Although the effects of mTOR among KTx recipients have been shown mostly for non-melanoma skin cancer [87,88,89], future studies evaluating the effects of different immunosuppressive regimens on mortality in KTx patients with RCC are needed. The gene discussed is MTOR; the disease is non-melanoma skin carcinoma.